Clinical Trial Update: RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of everolimus (RAD001) and pasireotide long-acting release (SOM230 LAR) in patients with advanced uveal melanoma. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Everolimus (everolimus)
• Pasireotide (pasireotide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Uveal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-08-01